

REMARKS

This application is a divisional application of US Patent Application No. 09/799,317, now issued US Patent No. 6,613,801.

The following remarks are submitted to address the issues raised in the Office Action mailed July 29, 2004.

Claims 3-10, 16-28, 31, and 34-51 have been canceled.


Claims 1-2, 11-15, 29-30, and 32-33 are pending in this application.

Claims 1, 2, 29, and 32 have been amended, and no new matter has been added.

Consideration of the pending claims is respectfully requested in view of the following comments.

ELECTION

In response to the Office Action mailed July 29, 2004, Applicants respectfully elect for further prosecution subject matter drawn to a compound, a pharmaceutical composition comprising a compound, and methods of using a compound, where the compound comprises at least one moiety of the formula



wherein L₁ is a C₁-C₄ alkyl group, L₂ is a direct bond, and each of Aryl₁ and Aryl₂ are substituted by at least one lipophilic group and at least one of Aryl₁ and Aryl₂ is substituted with a lipophilic group of the formula -Y-C₁₋₆-alkyl-NR₇R₈.


Applicants also elect the species of the compound (R)-3-(4-Benzyloxyphenyl)-2-tert-butoxycarbonylaminopropionic Acid 4-(3-Diethylamino-1-propoxy)-2-(3-

diethylamino-1-propoxy)aniline Amide shown as Example 21 on page 39 of the application.

Applicants traverse the election of subject matter and species on the grounds that searching all of the subject matter would not prove unduly burdensome.

AMENDMENTS

Applicants have elected subject matter drawn to a compound, a pharmaceutical composition comprising the compound, and methods of using a compound, where the compound comprises at least one moiety of the formula



wherein L₁ is a C₁-C₄ alkyl group, L₂ is a direct bond, and each of Aryl₁ and Aryl₂ are substituted by at least one lipophilic group and at least one of Aryl₁ and Aryl₂ is substituted with a lipophilic group of the formula -Y-C₁₋₆-alkyl-NR₇R₈.

Compounds in Examples 3-4, 8-9, 13-24, and 26 fall within the scope of the elected group.

Claims 1, 29 and 32 have been amended to be drawn to the elected subject matter, and the specification and original claims support the amendments to the Markush groups in claims 1, 29 and 32.

With regard to the amendment of L₁, the definition of R₃ (i.e., -C₁₋₄ alkylaryl) in original claim 4 supports amendment of L₁ to a C₁-C₄ alkyl group. With regard to the amendment of L₂, the definition of R₄ (i.e., -aryl) in original claim 5 supports amendment of L₂ to a direct bond.

With regard to the amendment of the lipophilic group in claim 1, the list of substituents in original claim 8 supports the amended definition of the lipophilic group as substituents to Aryl₁ and Aryl₂.

With regard to the amendment requiring at least one of Aryl₁ and Aryl₂ to be substituted with a lipophilic group of the formula -Y-C₁₋₆-alkyl-NR₇R₈, support for this limitation can be found in species described in Examples 3-4, 8-9, 13-24, and 26, where each aryl ring is substituted with a lipophilic group and at least one aryl ring is substituted by at least one lipophilic group of the formula -Y-C₁₋₆-alkyl-NR₇R₈. Further, each of these Examples 3-4, 8-9, 13-24, and 26 fall within the scope of the elected subject matter.

Claim 2 has been amended to clarify that at least one of Aryl₁ or Aryl₂ is further substituted with a lipophilic group selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylaryl, and C₁-C₆ alkoxyaryl, in addition to at least one of Aryl₁ and Aryl₂ being substituted with a lipophilic group of the formula -Y-C₁₋₆-alkyl-NR₇R₈. Support for this clarification can be found in species described in Examples 3-4, 8-9, 13-24, and 26, where each compound comprises an aryl group substituted by at least one lipophilic group of the formula -Y-C₁₋₆-alkyl-NR₇R₈ and an aryl group substituted by a lipophilic group selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ alkylaryl, and C₁-C₆ alkoxyaryl.

FEEs

This complete response is being filed within 2 months of the mailing of the Office Action on July 29, 2004. Applicants have included with this Amendment and Response a Petition for Extension of Time for 1-month under 37 C.F.R. § 1.136(a).


CONCLUSION

Favorable consideration and allowance of the application are respectfully requested.

Should the Examiner believe that anything further is necessary to place the application in a condition for allowance, the Examiner is invited to contact the undersigned attorney at the telephone number listed below.

Date: Sept 20, 2004

Respectfully submitted,



Samuel B. Rollins

Reg. No. 52,180

TransTech Pharma, Inc.
4170 Mendenhall Oaks Pkwy
High Point, NC 27265
Ph: 336-841-0300 ext. 159
Fax: 36-841-0310